{
    "nctId": "NCT00346229",
    "briefTitle": "Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer",
    "officialTitle": "A Phase I, Dose Escalation and Pharmacokinetics Study of Temperature Sensitive Liposome Encapsulated Doxorubicin (ThermoDox\u2122) and Hyperthermia in Patients With Local-Regionally Recurrent Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 29,
    "primaryOutcomeMeasure": "Maximum tolerated dose of temperature-sensitive liposomal doxorubicin (ThermoDox\u2122) in combination with hyperthermia",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Locally recurrent disease involving the chest wall and/or its overlying skin\n\n    * Clinically and biopsy proven disease on the chest wall area measuring \u2265 1 cm\n    * Overall surface extent of tumor \u2264 two 16 x 16 cm fields\n    * Tumor thickness \u2264 3 cm by clinical exam and CT scan or MRI\n    * Disease extent on the chest wall that exceeds the above criteria allowed provided no other local therapies are available\n    * Patients with axillary disease involvement only must meet the above criteria in order to be eligible\n    * Prior skin changes consistent with inflammatory breast cancer are allowed\n* Distant metastasis (excluding known brain metastases) allowed\n\n  * No resectable chest wall recurrence as the only site of metastatic disease\n  * No refractory pain secondary to metastatic disease\n* Must have undergone prior local radiotherapy to the chest wall or breast in the adjuvant or metastatic setting\n* Must have progressed on \u2265 1 course of hormonal therapy for metastatic disease (if tumor is estrogen receptor positive or progesterone receptor positive) AND \u2265 1 course of chemotherapy\n* Prior contralateral breast malignancy allowed provided not previously treated with chemotherapy\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Menopausal status not specified\n* Zubrod performance status 0-1 OR Karnofsky performance status 90-100%\n* Not pregnant\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Granulocyte count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 9 g/dL\n* Bilirubin normal\n* alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5 times upper limit of normal (ULN)\n* Creatinine \u2264 1.5 times ULN\n* left ventricular ejection fraction (LVEF) \u2265 50% by multiple gated acquisition scan (MUGA) or echocardiogram\n* No nonhealing wounds or active infection in the area of the chest wall\n* No clinically significant findings on baseline evaluations, including laboratory and physical examinations, vital signs, and ECG\n* No prior sensitivity (e.g., rash, dyspnea, wheezing, urticaria, or other symptoms) attributed to anthracyclines or other liposomally encapsulated drugs\n* No other prior or concurrent primary malignancy except for melanoma in situ, nonmelanoma skin cancer, squamous cell carcinoma, or noninvasive cervical carcinoma\n* No history of any of the following:\n\n  * Cardiac ischemia or acute coronary artery syndrome, myocardial infarction (MI), cerebral vascular accident, or abnormal cardiac stress testing within the last 6 months\n  * Coronary artery disease (including non-Q wave MI)\n  * Uncontrolled hypertension or cardiomyopathy\n  * Cardiac valvular surgery or open heart surgery\n  * Known structural heart disease\n* No other serious medical illness including, but not limited to, the following:\n\n  * Congestive heart failure\n  * Life-threatening cardiac arrhythmias\n  * Acute or chronic liver disease\n* No major psychiatric illness that required inpatient treatment within the past 3 months or that would preclude obtaining informed consent\n* No concurrent devices or conditions that might interfere with the hyperthermia portion of the trial, including any of the following:\n\n  * Functioning cardiac pacemaker\n  * Metal plates, rods, or prosthesis of the chest wall\n  * Severe numbness and/or tingling of the chest wall or breast\n  * Skin grafts and/or flaps on the breast or chest wall\n  * Unstable cardiovascular or pulmonary status\n* No known allergy to eggs or egg products\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 3 months since prior major surgery\n* No prior therapy with anthracyclines exceeding the following doses:\n\n  * Doxorubicin hydrochloride \\> 450 mg/m\\^2\n  * Epirubicin hydrochloride \\> 900 mg/m\\^2\n* More than 42 days since prior trastuzumab (Herceptin\u00ae)\n* More than 90 days since prior radiotherapy to the involved chest wall area\n* No other concurrent systemic anticancer therapy, including hormonal therapy, chemotherapy, or investigational anticancer therapy\n* No concurrent radiotherapy, including radiotherapy for pain control\n* No concurrent administration of any of the following drugs:\n\n  * Amphotericin B by injection\n  * Antithyroid agents\n  * Azathioprine\n  * Chloramphenicol\n  * Colchicine\n  * Flucytosine\n  * Ganciclovir\n  * Interferon\n  * Plicamycin\n  * Zidovudine\n  * Sulfinpyrazone\n  * Probenecid\n  * Cyclosporine\n  * Phenobarbital\n  * Phenytoin\n  * Streptozocin\n  * Live vaccines\n* Concurrent bisphosphonates for palliation of bony metastasis allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}